In this write up, we feature Sean Huang, Founder of Amwise. This biotech start up is a leading brand in precision medicine to serve the well being of Asia cancer patients. The patented examination technology of Amwise is developed based on Asian genes and can identify the risk of tumor recurrence or metastasis, assisting doctors with second opinions. Amwise aims to create hope for curing cancer in accompany with patients by personalized medical strategy.
Ahead of him joining us at Phar East 2018 in Singapore on 1-2 March, we asked him a few questions.
Q: What inspired the founding of Amwise?
Sean: Approximately 9 million people die from cancer every year, making cancer one of the leading causes of death globally. The number of death caused by cancer is estimated to have increased by 60% over the last 2 decades.
To tackle this global problem, Amwise was setup with the goal to become a leading precision medicine and medical artificial intelligence solution provider in oncology. Currently, we are in collaboration with more than 20 leading cancer centers, research institutions and technology partners in China, Singapore and Taiwan to find innovative solutions to help cancer patients and medical professionals.
Q: How is Amwise going to disrupt the pharma industry in Asia?
Sean: Amwise’s first product, RecurIndex®, is a patented proprietary technology used to estimate a patient’s risk of local-regional recurrence and distant metastasis once breast cancer is diagnosed. The analysis measures the expression levels of a combination of 28 genes which are currently known to be closely related to breast cancer recurrence in breast cancer patients, including genes associated with tumor growth, stromal invasion, inflammatory process, cell metabolism, and tumor cell apoptosis to calculate the risks associated with recurrence.
RecurIndex is breast cancer prognostic assay with the following key attributes
- 1st and only assay to evaluate necessity / dosage for both radiotherapy and chemotherapy
- Other products in the markets only evaluates risk of distant metastasis (necessity of chemotherapy)
- Wider coverage of patient groups including Stages 1, 2, 3 and all subtypes of breast cancer
- Validation of over 1,200 patients
Q: What type of company/investors would you like to meet at Phar-East this year?
Sean: As a company with strong core value in helping cancer patients, Amwise is looking for reputable lab and channel partners who are currently providers of genomic / genetic testing.
In addition, we are also looking for strategic investors who may be able to assist us with our expansion in China, Southeast Asia, Japan and Korea.
Q: Any advice for aspiring entrepreneurs looking to start a biotech company?
Sean: Healthcare environment is quite unique in many ways. There are strong compliances and regulatory barriers with conservative attitudes toward new technologies. In such an environment, it is imperative to work and partner with the right stakeholders such as leading medical service providers, key option leaders as well as various government, insurance and market access experts.
Sean and his team from Amwise will be present at Phar-East 2018 in Singapore on 1-2 March 2018. Find out more from our website: www.terrapinn.com/phareast.